Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.18 USD
+0.20 (1.11%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $18.17 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum C VGM
Zacks News
Editas (EDIT) Down 13.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment
by Zacks Equity Research
Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.
Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.
Myriad Genetics (MYGN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -375% and 9.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Hold Myriad Genetics (MYGN) Now
by Zacks Equity Research
Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer patients who are eligible for treatment with Lynparza in Japan.
Here's Why Investors Should Retain Myriad Genetics (MYGN) Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) better-than-expected results and strong testing volumes.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
by Zacks Equity Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Myriad Genetics (MYGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 100% and 6.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Moves 17% Higher: Will This Strength Last?
by Zacks Equity Research
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -4.41% and 12.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Makes Progress in Precision Oncology
by Zacks Equity Research
Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.
Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.
Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza
by Zacks Equity Research
Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.
Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.
Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 1.64% and 11.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.
Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.